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Abstract
Background: Late-onset Alzheimer's disease (LOAD) is an age related neurodegenerative disease
with a high prevalence that places major demands on healthcare resources in societies with
increasingly aged populations. The only extensively replicable genetic risk factor for LOAD is the
apolipoprotein E gene. In order to identify additional genetic risk loci we have conducted a genome-
wide association (GWA) study in a large LOAD case – control sample, reducing costs through the
use of DNA pooling.
Methods: DNA samples were collected from 1,082 individuals with LOAD and 1,239 control
subjects. Age at onset ranged from 60 to 95 and Controls were matched for age (mean = 76.53
years, SD = 33), gender and ethnicity. Equimolar amounts of each DNA sample were added to
either a case or control pool. The pools were genotyped using Illumina HumanHap300 and Illumina
Sentrix HumanHap240S arrays testing 561,494 SNPs. 114 of our best hit SNPs from the pooling
data were identified and then individually genotyped in the case – control sample used to construct
the pools.
Results: Highly significant association with LOAD was observed at the APOE locus confirming the
validity of the pooled genotyping approach.
For 109 SNPs outside the APOE locus, we obtained uncorrected p-values ≤ 0.05 for 74 after
individual genotyping. To further test these associations, we added control data from 1400 subjects
from the 1958 Birth Cohort with the evidence for association increasing to 3.4 × 10-6 for our
strongest finding, rs727153.
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BMC Medical Genomics 2008, 1:44 http://www.biomedcentral.com/1755-8794/1/44rs727153 lies 13 kb from the start of transcription of lecithin retinol acyltransferase
(phosphatidylcholine – retinol O-acyltransferase, LRAT). Five of seven tag SNPs chosen to cover
LRAT showed significant association with LOAD with a SNP in intron 2 of LRAT, showing greatest
evidence of association (rs201825, p-value = 6.1 × 10-7).
Conclusion: We have validated the pooling method for GWA studies by both identifying the APOE
locus and by observing a strong enrichment for significantly associated SNPs. We provide evidence
for LRAT as a novel candidate gene for LOAD. LRAT plays a prominent role in the Vitamin A cascade,
a system that has been previously implicated in LOAD.
Background
Late-onset Alzheimer's disease (LOAD) is an age related
neurodegenerative disease and the most common form of
dementia in the over 65 age group. It affects 20% of peo-
ple aged 75 – 84 years, rising to 50% in the over 85's, thus
placing major demands on healthcare resources in socie-
ties with increasingly aged populations [1]. It has a high
heritability with estimates ranging between 60 – 80% [2].
The only extensively replicable genetic risk factor for
LOAD is the apolipoprotein E gene, in which the ε4 gen-
otype is overrepresented in LOAD cases compared to con-
trols. The ε2 genotype is underrepresented and believed to
have a protective effect on disease development. However
the presence of the APOE-ε4 genotype is neither necessary
nor sufficient for the development of the disease, indeed
40 – 70% of European LOAD patients do not carry an ε4
variant, and additional genetic loci remain to be identi-
fied [3].
Recent advances in genotyping technology make it possi-
ble to conduct genome-wide association (GWA) studies,
testing the whole genome with hundreds of thousands of
single nucleotide polymorphisms (SNPs). For a complex
disease such as LOAD, in which multiple genetic and envi-
ronmental factors are thought to contribute to risk [2,4]
GWA studies offer the potential to detect susceptibility
genes with greater confidence than with linkage analysis.
It has been estimated that over 80% of genetic variation of
common SNPs of the human genome in European popu-
lations can be captured at an r2 > 0.8 by using current SNP
genotyping arrays [5].
In order to detect variants of small effect, particularly if the
association is indirect, and to overcome the issue of mul-
tiple testing, large sample sizes are required [6,7]. Cur-
rently, GWA studies are expensive, generally restricting
this type of work to groups or consortia with substantial
funding for that purpose. Genome-wide association anal-
ysis of pools of case and control DNA offers an economic
approach with the potential to identify disease loci [8-10].
In DNA pooling, equal amounts of DNA from each sam-
ple are combined to form pools from cases and controls,
which are genotyped to get an estimate of the true allele
frequency difference for each variant. This estimate is then
used to test a limited number of SNPs for genetic associa-
tion at a fraction of the cost of individual genotyping
[9,11,12].
In this study, 561,494 SNPs were genotyped in DNA pools
constructed from the Medical Research Council (MRC)
Genetic Resource for LOAD case – control samples. In
order to select SNPs for testing by individual genotyping,
we applied three complimentary approaches to select the
highest-ranked SNPs. We successfully genotyped individ-
ually 114 SNPs. We found association with LOAD of sev-
eral SNPs close to the APOE locus (2.08 × 10-9 – 8.24 × 10-
11) thus confirming the validity of the pooled genotyping
approach. In addition, we obtained evidence for several
novel genetic associations to LOAD, our most significant
findings being association of SNPs in the lecithin retinol
acyltransferase (phosphatidylcholine – retinol O-acyl-
transferase, LRAT) gene.
Results
Before we started work with Illumina arrays, we validated
the pool construction with the SNaPshot method. The
pools gave an accurate estimate of the real difference in
allele frequencies for 3 SNPs previously individually gen-
otyped in this sample. rs11084424, rs157580 and
rs157581 showed allele frequency differences between
cases and controls in pools of 4%, 9% and 17% respec-
tively which compared well with the real differences of
3%, 10% and 19%. Published estimates of the accuracy of
DNA pooling report similar high accuracy with errors of <
2% between predicted and true allele frequency differ-
ences using different methods [11].
Genome-wide pooled genotyping was carried out on the
Illumina HumanHap300 and Illumina Sentrix
HumanHap240S arrays assaying 561,494 SNPs. Frequen-
cies for each SNP were averaged over four replicate case
and three replicate control arrays for the Illumina
HumanHap300 and eight each for the Sentrix
HumanHap240S arrays. The predicted averaged patient
and control allele frequencies showed as expected a very
high Pearson correlation with each other of r = 0.998,
indicating a low technical variability of the method. Fig-
ure 1 shows predicted allele frequencies in case and con-Page 2 of 13
(page number not for citation purposes)
BMC Medical Genomics 2008, 1:44 http://www.biomedcentral.com/1755-8794/1/44trol pools determined using the Illumina HumanHap300
platform. Data from the Illumina Sentrix
HumanHap240S arrays showed similarly high correla-
tions (r = 0.997). Predicted allele frequencies were com-
pared with actual population allele frequencies (1958
Birth Cohort controls genotyped with the same
HumanHap300) and gave a very good correlation of
0.969 (Figure 2). This indicates that even uncorrected data
from pooling on this platform predict fairly well the true
absolute allele frequencies of SNPs.
Figure 3 shows the combined Z-test p-value results for the
whole genome. On the X-axis we have plotted the posi-
tion in the genome by chromosome, and on the Y-axis the
negative logarithm of the p-value. The strongest evidence
for association with LOAD was observed with SNPs on
chromosome 19 surrounding the APOE gene. In all, 7
SNPs within 71 kb were predicted by the pools to have
allele frequency differences between 6% – 14% and "com-
bined" p-values ranging from 9.0 × 10-5 to 3.6 × 10-22. No
other region of the genome showed such a large number
of significant markers over a relatively small region. Five
of the seven SNPs were individually genotyped and were
confirmed to be highly significant (p-value range 2.08 ×
10-9 – 8.24 × 10-11, Table 1). All are in high linkage dise-
quilibrium (LD) with the SNPs that define the APOE gen-
otypes which are not themselves typed on the Illumina
platform (Figure 4). The distributions of APOE alleles in
this population are as follows:
Scatter plot of pooled genotype dataFigure 1
Scatter plot of pooled genotype data. Predicted allele frequencies of ~31,000 randomly selected SNPs in LOAD case and 
control DNA pools predicted by the Illumina HumanHap300 array. Averaging three case and four control arrays, we obtain a 
correlation r = 0.998.Page 3 of 13
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77.3, 13.2% in cases and controls respectively, giving an
allelic p-value of p = 1.9 × 10-73 and an odds ratio
(95%CI) = 3.85 (3.55 – 4.15) for the APOE-ε4 allele.
Table 1 shows results for our most significant SNPs, in
addition to those at the APOE locus, following individual
genotyping. The most significant SNP, rs727153, reached
a p-value of 2.4 × 10-5.
To further test the associations, we added control data
from a set of controls comprising approximately 1400
subjects from the 1958 Birth Cohort for the 79 SNPs that
showed individual genotype p-value ≤ 0.05. The associa-
tion for five SNPs becomes more significant with the
inclusion of the additional controls. The majority of SNPs
however became less significant indicating that for these
SNPs we had probably identified false positives, although
this could also happen to true-positive findings, as the ini-
tial discovery study tends to over-estimate the effect size.
Our strongest finding, rs727153 remained the most sig-
nificant individually genotyped SNP, with the evidence
for association increasing from 2.4 × 10-5 to 3.4 × 10-6.
rs727153 is an intergenic SNP approximately 13 kb from
the start of transcription of lecithin retinol acyltransferase
(phosphatidylcholine – retinol O-acyltransferase, LRAT).
We genotyped additional SNPs in this region to test if our
Scatter plot of pooled vs individual (population) genotype dataFigure 2
Scatter plot of pooled vs individual (population) genotype data. Predicted allele frequencies were averaged across 
technical replicates for the control pool and compared to actual population frequencies determined from the 1958 Birth 
Cohort, r = 0.969.Page 4 of 13
(page number not for citation purposes)
B
M
C
 M
e d
i c
a l
 G
e n
o m
i c
s  
2 0
0 8
,  1
: 4
4
h t
t p
: / /
w
w
w
. b
i o
m
e d
c e
n t
r a
l . c
o m
/ 1
7 5
5 -
8 7
9 4
/ 1
/ 4
4
P a
g e
 5
 o
f  1
3
( p
a g
e  
n u
m
b e
r  
n o
t  f
o r
 c
i t a
t i o
n  
p u
r p
o s
e s
)
Table 1: Individually genotyped SNPs that show significant association with LOAD.
SNP ID Chrom Position Gene 
Symbol
SNP Type Minor 
Allele
Pooled fcas Pooled 
fcon
Ind fcas Ind fcon Ind f 1958 Comb Z-
test pools
p Cases vs 
MRC Cons
p Cases vs 
All Cons
Rs6859 α 19 50073874 PVRL2 T/C A 0.423 0.324 0.519 0.419 0.417 6.00E-07 1.73E-10 6.09E-14
Rs157580 α 19 50087106 TOMM40 A/G G 0.653 0.583 0.693 0.595 0.616 6.43E-05 8.24E-11 3.87E-11
Rs8106922α 19 50093506 TOMM40 A/G G 0.622 0.507 0.698 0.599 0.596 5.89E-09 1.21E-10 3.96E-14
Rs405509 α 19 50100676 APOE A/C G 0.547 0.468 0.558 0.463 0.521 7.33E-06 2.08E-09 4.77E-06
Rs439401 α 19 50106291 APOE T/C T 0.303 0.372 0.276 0.361 0.357 8.97E-05 7.97E-09 9.15E-11
Rs727153 ‡ 4 156012026 intergenic T/C C 0.425 0.515 0.475 0.540 0.535 0.0009 0.00002 3.37E-06
Rs3754675 2 101008361 NPAS2 T/C C 0.814 0.741 0.939 0.905 0.936 5.70E-06 0.00003 0.0144
Rs4699852 4 95699967 intergenic T/C A 0.392 0.468 0.431 0.493 0.451 0.0008 0.00004 0.0032
Rs2905990 5 11160513 CTNND2 A/G T 0.298 0.369 0.300 0.356 0.327 3.79E-05 0.00009 0.0014
Rs9600764 13 76208794 intergenic T/C G 0.904 0.860 0.974 0.953 0.964 9.98E-05 0.00019 0.0027
Rs1032412 2 163464614 KCNH7 A/G G 0.536 0.484 0.726 0.673 0.711 0.0024 0.00019 0.0097
Rs12510838 4 73326573 NPFFR2 A/G G 0.627 0.558 0.828 0.783 0.810 0.0008 0.00024 0.0047
Rs7140253 14 106305044 intergenic T/C G 0.772 0.711 0.898 0.862 0.875 3.18E-05 0.00024 0.0007
Rs1455280 4 61600197 intergenic T/C G 0.870 0.820 0.900 0.864 0.882 0.0001 0.00027 0.0026
Rs13397414 2 154056922 intergenic A/G G 0.529 0.428 0.895 0.859 0.867 3.44E-09 0.00028 0.0003
Rs587259 19 39348246 LSM14A T/C T 0.515 0.450 0.397 0.344 0.364 0.0002 0.00028 0.0009
Rs13115107 4 183493069 intergenic T/C G 0.466 0.537 0.687 0.736 0.722 0.0001 0.00032 0.0005
Rs1373900 2 193561888 intergenic T/C T 0.259 0.322 0.329 0.380 0.346 5.38E-05 0.00037 0.0087
Rs1911014 4 127131703 intergenic A/G A 0.145 0.205 0.124 0.162 0.155 3.56E-06 0.00037 0.0003
Rs17228994 5 14095376 intergenic A/C C 0.668 0.736 0.849 0.885 0.870 3.60E-05 0.00060 0.0025
Rs407146 16 13223156 LOC729993 A/C T 0.294 0.239 0.416 0.365 0.399 0.0007 0.00060 0.0137
Rs7937776 11 94336790 HSPC148 A/G C 0.576 0.642 0.797 0.837 0.826 0.0006 0.00067 0.0007
Rs3819902 21 42973084 PDE9A A/G C 0.623 0.555 0.914 0.883 0.887 0.0009 0.00068 0.0004
Rs16916856 8 52901703 PCMTD1 T/C C 0.745 0.677 0.887 0.852 0.868 7.80E-06 0.00069 0.0036
Rs393195 19 49184982 ZNF155 A/C G 0.600 0.525 0.760 0.715 0.745 0.0002 0.00071 0.0147
Rs12146414 10 17108257 CUBN A/G G 0.829 0.759 0.933 0.905 0.920 1.37E-05 0.00086 0.0067
Rs7798395 7 70326814 WBSCR17 T/C C 0.691 0.777 0.923 0.948 0.941 2.20E-06 0.00090 0.0011
Rs741477 ‡ 2 64977962 intergenic A/G G 0.852 0.795 0.898 0.867 0.858 5.44E-05 0.00124 3.05E-05
Rs10161338‡ 12 114328023 intergenic T/C C 0.759 0.682 0.902 0.872 0.875 3.52E-05 0.00176 0.0009
Rs10406335‡ 19 49325793 ZNF225 A/G G 0.637 0.571 0.905 0.878 0.876 0.0003 0.00390 0.0009
Rs9324088 ‡ 14 106041164 intergenic T/C G 0.616 0.544 0.751 0.718 0.699 0.0003 0.01295 0.0002
Pooled fcas: Predicted Allele Frequency in MRC Case Pools. Pooled fcon – Predicted Allele Frequency in MRC Control Pools
Ind fcas: Actual Allele Frequency in MRC Cases.
Ind fcon: Actual Allele Frequency in MRC Controls.
Ind f1958: Allele Frequency in 1958 Birth Cohort
Comb Z-test pools: the p-value of combined Z-test for allelic association in pooled data.
p Cases vs MRC Cons: refers to p-value for allelic association in LOAD case subjects vs LOAD MRC control subjects matched for age, gender ethnicity.
p Cases vs All_Cons: refers to p-value for allelic association in LOAD case subjects vs MRC LOAD control subjects combined with genotype data obtained from the 1958 Birth Cohort
α : SNPs in the region of APOE
‡ : SNPs that show an approximately 10 fold increase in significance when additional controls from the 1958 Birth Cohort are combined with controls from the MRC sample (p Cases vs All Cons)
BMC Medical Genomics 2008, 1:44 http://www.biomedcentral.com/1755-8794/1/44significant association extended into the LRAT gene.
rs727153 is within an LD block flanked by SNPs
rs11935519 and rs149225
(Chr4:156,005,695..156,040,821 – HapMap data Rel
21a/phaseII Jan07), which includes LRAT (Figure 5).
Using a pair-wise approach in Haploview we identified 7
tagging SNPs required to cover the LD block, capturing all
common SNPs with an r2 > 0.8 and individually genotyp-
ing them in our LOAD case – control sample. The results
are presented in Table 2. Five SNPs are significantly asso-
ciated with LOAD in this region, with a SNP in intron 2 of
LRAT, rs201825 showing the strongest evidence (p-value
= 1.7 × 10-6). After the addition of extra controls data from
the 1958 birth cohort for the 4 SNPs in LRAT which have
been genotyped in that sample, 3 became more significant
(rs201825, p-value = 6.1 × 10-7) and the fourth remained
unchanged.
Analysis of the tagSNPs in this LD block using all possible
2- and 3-marker haplotypes resulted in no evidence for
association greater than that reached by rs201825 (data
not shown).
Table 3 provides the distribution of the individual geno-
typing p-values for 109 SNPs outside the APOE locus, in
addition to the p-value distributions for our three meth-
ods used to choose the SNPs for individual genotyping.
After individual genotyping, we obtained uncorrected p-
values ≤ 0.05 for 74 of the 109 SNPs compared with
expected 5.5 for a random selection of SNPs, an enrich-
ment of ~13 fold across all selection methods. The cluster
method appeared to generate the highest percentage of
significantly associated SNPs (84.8%), at greater levels of
significance, identifying the 3 most significant SNPs after
individual genotyping. One of the three most significant
SNPs (rs3754675) was also in the top 115 SNPs ranked by
the "combined" Z-test. The most significant SNP by indi-
vidual genotyping chosen by the allele frequency method
(rs12510838) had a p-value of 0.00024, an order of mag-
nitude less than our most significant SNP chosen by the
other methods (Table 1). Thus it appears that the cluster
method provided the best way of identifying true associa-
tions and that the combined Z-test improves on the iden-
tification of single significant SNPs over a simple method
of following-up only the highest differences in allele fre-
quencies.
Discussion
In this study we used DNA pooling to offset the high costs
of conducting a GWA study for LOAD. Using Illumina
HumanHap300 and Illumina Sentrix HumanHap240S
arrays we estimated the allele frequencies of 561,494
SNPs across the genome in pools constructed from 1,082
LOAD cases and 1,239 age-matched controls. We une-
quivocally identified the APOE locus as the major genetic
risk factor for the disease. As noted by others this can be
seen as a positive control that the pooling method is a via-
ble alternative to individual genotyping in GWA studies
for complex disorders [13]. The association of APOE with
LOAD is well replicated [14,15] and has been observed in
a GWA study that used an alternative genotyping platform
[16]. Neither the Illumina platform used here nor the
Plot of combined Z-test p-values against chromosomal location for pooled dataFigure 3
Plot of combined Z-test p-values against chromosomal location for pooled data. Out of 561,494 SNPs that were 
genotyped in our case – control pools, only 3 would have remained significant after Bonferroni correction for multiple testing, 
two of these SNPs are near the APOE gene on Chromosome 19. For a genome-wide association study on 500,000 markers 
(assuming that markers are independent) the significance level is 10-7. The line of genome-wide significance is plotted therefore 
at this level, although the combined Z-statistic provides only an approximation of the p-values produced from individual geno-
typing.Page 6 of 13
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BMC Medical Genomics 2008, 1:44 http://www.biomedcentral.com/1755-8794/1/44Affymetrix system used in that study directly test the SNPs
that define the APOE-ε4 genotype, highlighting the
strength of high density GWA studies to detect indirect
association. Our findings are in agreement with others
that APOE is the major pathogenic locus for LOAD, and
that further loci of smaller effect remain to be identified
[16,17].
Following pooled genotyping, it is necessary to follow up
positive results with individual genotyping to confirm the
observed associations. We used three methods to identify
SNPs to follow up. The cluster method appeared to gener-
ate more true associations than the other methods we
used. This is perhaps not surprising, as this method
should minimise false positives due to technical artefacts
caused by pooled genotyping, as each SNP showing evi-
dence of association was required to be supported by one
or more highly significant neighbouring SNP. In contrast,
a singleton highly-ranked SNP found by any other
method could be due to a technical artefact, no matter
how carefully it is filtered. However, the cluster method
can miss true positive signals from functional variants that
are not in high LD with other tested SNPs. Therefore, we
believe that unsupported SNPs have to be followed up as
well, unless they are in high LD with other SNPs on the
array, which do not support the association. As has been
proposed by others, the data presented here suggests that
the best way of choosing unsupported SNPs would be to
use a statistical test that takes into account technical vari-
ation, such as the combined Z-test [11]. We acknowledge
that this study has not exhaustively followed up all posi-
tive signals – to do this would negate the cost efficiency of
LD plot for SNPs in the region of APOEFigure 4
LD plot for SNPs in the region of APOE. SNPs in the region of APOE, significant from Illumina pooled genotyping were 
individually genotyped and show high LD (D' given) with SNPs that define APOE-ε2/ε3/ε4 status (rs429358 and rs7412).Page 7 of 13
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cantly associated SNPs could be confirmed by individual
genotyping. In fact, we only genotyped individually half
of the SNPs that we considered worth following up. How-
ever it appears clear that a signal with the strength of asso-
ciation, in terms of a number of highly significant SNPs in
a narrow region, as observed at the APOE locus, has not
been overlooked.
In order to confirm our individual genotyping results,
data from the 1958 Birth Cohort were used to form an
additional set of controls genotyped with the Illumina
platform. These controls have previously been used by the
Wellcome Trust Case Consortium for a GWA study for 7
common diseases [18]. There are a number of explana-
tions for our observation that for the majority of SNPs sig-
nificant in this study the strength of association decreased
with additional control data. Firstly, and we believe most
likely, the initial findings may have been false positives
due to an inflation of the effect size in the original analysis
due to sampling variance in the control allele frequencies
(i.e. some of the most significant SNPs have the highest
sampling variance in either cases or controls). Secondly,
the use of unscreened controls in an association study of
a disorder of old age is expected to reduce power [19], this
is particularly clear in the APOE locus. Some degree of
genotyping discrepancies between the two platforms used
is also possible (Sequenom in our lab and Illumina in the
1958 Birth Cohort), however very unlikely to account for
such large differences.
We identified multiple SNP associations (best p-value =
6.12 × 10-7) in the gene encoding lecithin retinol acyl-
transferase (LRAT, 4q32.1, MIM: 604863). This is a highly
plausible functional candidate gene for LOAD. LRAT
plays a prominent role in the Vitamin A (retinoid) cascade
by producing retinyl esters, storage forms of retinoid. The
retinoid system has been previously implicated in LOAD.
Retinoid levels in plasma, serum and brain are lowered in
LOAD patients, and the restriction of dietary retinoid in
mice results in memory impairment [20,21]. Furthermore
disruption of the retinoid signalling pathway in adult rats
by a dietary deficiency of vitamin A leads to deposition of
amyloid beta in the cerebral blood vessels. There is a
down regulation of retinoic acid receptor alpha in the
forebrain neurons of the retinoid-deficient rats and a loss
of choline acetyl transferase expression, which precedes
amyloid beta deposition. In neocortex of pathology sam-
ples of patients with Alzheimer's disease, the same retin-
oic acid receptor alpha deficit in the surviving neurons is
observed suggesting that retinoids are important for the
maintenance of the adult nervous system and their loss
may in part play a role in Alzheimer's disease [22]. Never-
theless, despite the functional plausibility, our genetic
findings in LRAT fall short of the degree of statistical sig-
nificance required to provide unequivocal evidence for
association, given the large number of comparisons made
in a GWA study. Thus our findings, whilst highly sugges-
tive, will require confirmation in independent samples.
Conclusion
In summary, we have validated the pooling method for
GWA studies by both identifying the APOE locus, a
known risk gene for LOAD, and by observing a strong
enrichment for significantly associated SNPs. We have
also compared methods for prioritising SNPs for individ-
ual genotyping. Finally, we provide evidence for LRAT as
a novel candidate gene for LOAD. GWA studies with
pooled DNA provide a viable, quick and inexpensive
approach to identifying susceptibility genes. Inaccuracies,
Table 2: Association analysis of tag SNPs used to cover the LD block containing LRAT.
SNP ID Position 
(Mb on 
Chr 4)
Minor 
Allele
Minor 
Allele 
Freq 
Cases
Minor 
Allele 
Freq 
Controls
Minor 
Allele 
Freq 1958
p Cases vs 
MRC Cons
OR Cases 
vs MRC 
Cons 
(95% CI)
p Cases vs 
Comb 
Cons
OR Cases 
vs Comb 
Cons 
(95% CI)
Rs12501328 156,019,936 G 0.10 0.08 0.07 0.02661 1.27 (1–1.6) 0.0032 1.32 
(1.1 – 1.6)
Rs201825 156,024,540 C 0.52 0.44 0.46 1.65E-06 1.34 
(1.2–1.5)
6.12E-07 1.3 
(1.2 – 1.4)
Rs201824 156,026,315 T 0.40 0.35 0.00066 1.24 
(1.1–1.4)
N/A N/A
Rs201823 156,026,490 G 0.40 0.35 0.37 0.00042 1.24 
(1.1–1.4)
0.0004 1.21 
(1.1 – 1.3)
Rs156500 156,034,920 C 0.13 0.11 0.09457 1.17 (1–1.4) N/A N/A
Rs156501 156,035,950 A 0.22 0.19 0.19 0.01635 1.2 (1–1.4) 0.0058 1.2 
(1.1 – 1.4)
Rs149225 156,040,821 C 0.42 0.40 0.34900 1.06 
(0.9–1.2)
N/A N/A
For descriptions see Table 1. OR – Odds Ratio, N/A – test not conducted.Page 8 of 13
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individual genotyping will remain undetected.
Methods
Subjects
Written informed consent was obtained from all subjects
for publication of this case report. A copy of the written
consent is available for review by the Editor-in-Chief of
this journal. The sample consisted of individuals ascer-
tained from both community and hospital settings in the
UK collected as part of the MRC genetic resource for
LOAD. Clinical data and DNA samples were collected
from 1,082 individuals (71% females) with late-onset AD
(LOAD) and 1,239 control subjects (referred to in the text
as "MRC controls", 62% females). Age at onset ranged
from 60 to 95 years (mean = 75.84 years, SD = 6.79). Con-
trols were matched for age (mean = 76.53 years, SD =
6.33), gender and ethnicity. AD cases and controls
described here were ascertained by three collaborating
centres: Department of Psychological Medicine, Cardiff
University, Cardiff (coordinating centre); Institute of Psy-
chiatry, London; and Cambridge University, Cambridge,
as previously described [23]. Ethical approval was
obtained from the Multi-centre Research Ethics Commit-
tee (MREC), relevant local ethics committees and NHS
trusts, in the regions where subjects were recruited.
All cases were Caucasian, of UK origin (parents born in
the UK) and diagnosed with probable AD in accordance
with the National Institute of Neurological and Commu-
nication Disorders and Stroke and the Alzheimer's disease
and Related Disorders Associations (NINCDS-ADRDA)
clinical diagnostic criteria for AD [24]. All diagnoses were
made based on a semi-structured interview with known
validity for AD pathology (i.e. positive predictive value of
92–95% [25,26] which included: The Mini Mental State
Examination (MMSE) [27]; The Cambridge Mental Disor-
ders of the Elderly Examination (CAMDEX; informant
interview) [28]; The Blessed Dementia Scale [29]; The
Bristol Activities of Daily Living Scale [30]; Webster Rating
Scale [31]; Global Deterioration Scale (GDS) [32]; Cornell
Scale for Depression in Dementia [33]; Neuropsychiatric
Inventory (NPI) (12-item version) [34]. Interviews were
primarily conducted with the AD sufferer's next of kin.
Ethical permission was obtained from the Multi-centre
Research Ethics Committee, relevant local ethics commit-
tees, and National Health Service trusts.
Control subjects were either spouses of AD patients or
selected from primary-care practices situated in the same
geographical areas as AD patients. All controls were 60
LD plot for SNPs in the region of LRATFigure 5
LD plot for SNPs in the region of LRAT. Linkage Dise-
quilibrium plot (D' values shown) for tagSNPs chosen to 
cover an LD block containing LRAT. The most significant SNP 
from GWA study, rs727153, is in high LD with SNPs in LRAT.
Table 3: Distribution of p-values of individually genotyped SNPs (excluding those in the region of APOE).
P-Value Range
Selection Category N < 0.05 0.05 – 0.005 5 × 10-3- 5 × 10-4 5 × 10-4- 5 × 10-5 5 × 10-5- 5 × 10-6
ALL SNPs 109 74 (67.9%) 38 (34.9%) 22 (20.2%) 11 (10.1%) 3 (2.8%)
CLUSTERS 33/58 28 (84.8%) 12 (36.4%) 8 (24.2%) 5 (15.2%) 3 (9.1%)
COMB 66/115 44 (66.6%) 22 (33.3%) 13 (19.7%) 8 (12.1%) 1 (1.5%)
FREQ 46/136 24 (52.2%) 13 (28.3%) 9 (19.6%) 2 (4.3%) 0 (0%)
Selection category gives the method used to choose SNP for individual genotyping (see text for description). N: number of SNPs tested in each 
selection category. Note: of the 66 SNPs in the COMB category, 11 and 25 SNPs respectively had been identified by the CLUSTER and FREQ 
methods.Page 9 of 13
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screened for cognitive decline using the MMSE, and a cut-
off score of ≥ 28 was adopted. Assessment of controls also
included a section of the Cambridge Mental Disorders of
the Elderly Examination and the Geriatric Depression
Scale [35]. Exclusion criteria were the presence of demen-
tia, depression, delirium or other illnesses likely to signif-
icantly reduce cognitive function.
DNA Pool Construction
DNA was obtained from blood samples by phenol/
choloroform extraction, followed by precipitation in eth-
anol and storage in TE buffer. DNA quality was assessed
by PCR amplification of microsatellite markers under
standard conditions, with those samples showing robust
amplification being included in pools (1,082 LOAD cases
and 1,239 controls). Initial DNA concentrations were
determined by UV spectrophotometry using absorbance
at 260 nm readings. Dilutions were made using water to
bring the concentration of each sample to a target of 20
ng/ul. The concentration of each sample was then deter-
mined using the PicoGreen dsDNA Quantitation Reagent
(Molecular Probes, Eugene, Ore.) in a Labsystems Ascent
Fluoroskan (LifeSciences Int., Basingstoke, UK). Each
sample was then diluted to 4 ng/ul (± 0.5 ng/ul), allowed
to equilibrate at 4°C for 48 h before another quantifica-
tion using the PicoGreen method. Samples out of the 4
ng/ul (± 0.5 ng/ul) range were diluted/concentrated, incu-
bated and re-quantified until they were within the
required range. Equal volumes of each sample were then
added to either a case or control pool using a Biomek® FX
Laboratory Automation Workstation (Beckman Coulter,
Inc., Fullerton, CA). We chose to make single pools of
cases and controls and hybridise them multiple times,
rather than construct many small pools and hybridise
them on single arrays, as this method has been shown to
be more powerful [36].
Pool validation with the SNaPshot method
In order to test the accuracy of our pool construction, we
genotyped 3 significantly associated SNPs in the pools for
which we had individual genotype data on the samples
used to create the pools (rs11084424, rs157580 and
rs157581). SNaPshot genotyping was carried out as previ-
ously described [12]. Briefly, forward and reverse primers
were designed using primer 3 software http://
primer3.sourceforge.net/. Extension primers for the
SNaPshot assay were designed using FP PRIMER 1.0.1 b
software http://m034.pc.uwcm.ac.uk/FP_Primer.html.
PCR was performed under standard conditions, using 15
ng pooled genomic DNA and HotStar Taq DNA polymer-
ase (Qiagen). Primer extension products were run on a
3100 DNA sequencer (Applied Biosystems) and the data
were processed by the GeneScan Analysis 3.7 (Applied
Biosystems). SNP allele frequencies in DNA pools were
estimated from peak heights obtained by using Genotyper
2.5 (PE Biosystems, Cheshire, UK). Estimated allele fre-
quencies from pools were corrected for unequal represen-
tation of alleles using the mean of the ratios obtained
from four analyses of a heterozygote [37].
Pooled DNA Genotyping using Illumina Platform
Genome-wide genotyping was performed using Illumina
HumanHap300 and Illumina Sentrix HumanHap240S
arrays (Illumina Inc., San Diego, CA, USA) according to
the manufacturer's protocols. Chips were scanned in
standard mode on a BeadStation 500 GX (Illumina) at the
University of Bonn and raw data were extracted for statis-
tical analysis with BeadStudio v3.1 software. Because of
the expected inter-experiment variation, replicate arrays
were genotyped for each pool: four arrays on the Illumina
HumanHap300, and 8 arrays on the Illumina Sentrix
HumanHap240S array. The reason for using more
HumanHap240S arrays is that we first performed the
work on HumanHap300, and noticed the need for more
replications. Replicate arrays were excluded if the esti-
mated allele frequencies produced a Pearson correlation
of r ≤ 0.991 with two or more other replicate arrays of the
same pool (i.e. only arrays which correlated at r ≥ 0.992
with each other were retained for analysis). This cut-off
was adopted during other pooling work in our depart-
ment, but in this experiment resulted in the exclusion of
data from only a single array (from a control pool) geno-
typed on the HumanHap300 array.
Analysis of pooled DNA
Approximation of allele A frequencies for each replicate
was produced on the basis of the raw data as follows:
f_alleleA = Xraw/(Xraw+Yraw), averaged over the number
of replicates in each pool (Xraw and Yraw are the intensi-
ties of the two dyes Cy5 and Cy3, used to genotype SNPs
on the Illumina platform).
Selection of SNPs for individual genotyping
SNPs from the pooling data were prioritised for individual
genotyping based on three different methods, outlined
below, since, at the time of this experiment we did not
know which method would perform best. For all meth-
ods, we excluded rare SNPs (true allele frequency less than
5% in the CEU population of the HapMap, http://
www.hapmap.org/) and the 5% of SNPs showing the
highest technical variability as indicated by the size of the
standard deviation amongst measures from the replicate
arrays.
1) Cluster Method
We plotted the differences in allele frequencies between
cases and controls for each SNP against their position in
the genome. We identified 58 clusters where at least two
SNPs within 100 kb had a predicted allele frequency dif-Page 10 of 13
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selected for individual genotyping.
2) Allele Frequency Difference Method
Separately for the Illumina HumanHap300 and Illumina
Sentrix HumanHap240S arrays (to account for any differ-
ences caused by technical artefacts between the two
arrays) the pooled data were sorted by predicted allele fre-
quency differences in cases and controls. The top 136
SNPs showing the greatest allele frequency differences
(8% difference between cases and controls) and satisfying
the above filtering criteria were put forward for potential
individual genotyping. SNPs that had previously been
flagged as being in a cluster were not included.
3) "Combined Z-test"
The third method was based on p-values estimated using
the following statistic which combines experimental and
sampling errors, a general description of which has previ-
ously been presented [11,36,38]:
This statistic combines:
a) chi-square statistic T for testing differences between two
proportions (allele frequencies) in cases and in controls
accounting for the sampling variance:
where  is the mean of the allele frequen-
cies over nk pool replicates,  is the binomial
sampling variance and Nk is number of controls and cases
respectively (k = 1,2).
b) Z-statistics for testing the difference in mean allele fre-
quencies between cases and controls:
where  is the square of the
standard error due to experimental error.
Thus we have taken into account the two single available
sources of error: sampling error and experimental error in
a simple way which is equivalent to a simplified version
of the complex regression model suggested by MacGre-
gor[36].
Excluding 36 SNPs already selected by the allele frequency
(25 SNPs) or cluster (11 SNPs) methods, and any filtered
ones, 79 of the highest-ranking SNPs identified by the
combined Z-test method were put forward for individual
genotyping.
Individual Genotyping
The 273 SNPs chosen by the three methods, (in addition
to 5 SNPs at the APOE locus which had been identified by
all three methods) were presented to the Sequenom Assay
Design 3.1 software (Sequenom, San Diego, CA), which
selected 130 for genotyping. We deliberately presented
about twice as many SNPs to the software, as we wanted
to type, in order to maximise the chance of producing
well-performing panels.
Genotyping was performed with the MassARRAY and
iPlex systems (Sequenom, San Diego, CA) according to
the manufacturer's recommendations. Assays were opti-
mized in 30 reference CEU parent – offspring trios, which
have been used extensively in the HapMap project. All
sample plates contained cases, controls, blanks, CEU and
duplicate samples. Quality control (QC) measures
included independent double genotyping blind to sample
identity and blind to the other rater, and comparison of
our CEU genotypes to those in the HapMap database
http://www.hapmap.org. SNPs showing deviation from
Hardy-Weinberg equilibrium (p-value < 0.001 in con-
trols) or with genotyping success rates of less than 90%, or
showing differences in genotypes in the CEU samples
from those in the HapMap database were excluded from
analysis. Individual DNA samples for whom the genotyp-
ing success rate across all SNPs was < 75% were also
excluded (40 cases and 49 controls).
Of the 130 SNPs chosen from the pooling GWA study,
114 passed QC. Of these 5 were located within 32 kb of
APOE, 33 were selected from the cluster method, 30 were
identified solely by the combined Z-test method and 46
were chosen based on the allele frequency difference.
Calculation of allele frequencies, genotype counts, tests
for departure from HWE, allelic association and odds
ratio were carried out using PLINK (vers 0.99s, http://
pngu.mgh.harvard.edu/purcell/plink/, [39].
Linkage Disequilibrium analysis was conducted using
Haploview version 4.0 http://www.broad.mit.edu/mpg/
haploview/, [40].
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(http://www.b58cgene.sgul.ac.uk/, accessed September
2007) which contains genotyping data on the British
1958 Birth Cohort DNA Collection, deposited by the
Wellcome Trust Sanger Institute.
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